Major Shareholding Notification • Jan 11, 2016
Major Shareholding Notification
Open in ViewerOpens in native device viewer
DISCLOSURE OF SHAREHOLDING IN MEDISTIM ASA
This joint disclosure is made by HealthInvest Partners
AB ("HealthInvest") for and on behalf of itself as
well as for and on behalf of HealthInvest Value Fund
and HealthInvest MicroCap Fund, in accordance with
Section 4-3 of the Norwegian Securities Trading Act.
HealthInvest is an independent Swedish fund management
company under the supervision of the Swedish Financial
Supervisory Authority (Finansinspektionen) since 2006.
HealthInvest offers actively managed healthcare funds
aimed at institutional and private clients.
HealthInvest´s investment approach includes a strong
emphasis on low valuations and in depth due diligence
to find potential catalysts to boost shareholder
value.
On January 11, 2016 (with settle date January 13,
2016), HealthInvest sold 700,000 shares in MEDISTIM
ASA ("MEDISTIM") for and on behalf of the HealthInvest
Value Fund. As a result of the transaction,
HealthInvest MicroCap Fund and HealthInvest Value Fund
crossed below the 5% threshold of Section 4-3 of the
Norwegian Securities Trading Act calculated on an
aggregate basis.
After the transaction mentioned above, HealthInvest
MicroCap Fund and HealthInvest Value Funds
shareholding in MEDISTIM amounts to 284,049 shares and
3,156 shares respectively. This equals 1.55% and 0.02%
of the issued shares and votes in MEDISTIM.
After the transaction, the aggregate shareholding in
MEDISTIM over which HealthInvest is authorized to
exercise voting rights on a discretionary basis
amounts to 287,205 shares, equaling 1.57% of the
issued shares and votes in MEDISTIM.
The above calculations are based on a total number of
outstanding shares in MEDISTIM of 18,337,336 shares.
No rights to shares in MEDISTIM are held by
HealthInvest MicroCap Fund, HealthInvest Value Fund or
any other fund managed by HealthInvest.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.